Citation Impact
Citing Papers
Let-7 Expression Is a Significant Determinant of Response to Chemotherapy through the Regulation of IL-6/STAT3 Pathway in Esophageal Squamous Cell Carcinoma
2012
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
2011 Standout
Adaptive Therapy
2009
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
2002 Standout
Untangling the ErbB signalling network
2001 Standout
β-Arrestin-mediated Signaling Regulates Protein Synthesis
2008 StandoutNobel
PROGNOSTIC SIGNIFICANCE OF THE CO-EXPRESSION OF p53 AND c-erbB-2 PROTEINS IN BREAST CANCER
1996
HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric Cancer
2006
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
Involvement of tyrosine phosphorylation of p185(c-erbB2/neu) in tumorigenicity induced by X-rays and the neu oncogene in human breast epithelial cells.
1998
MNK1 and MNK2 Regulation in HER2-overexpressing Breast Cancer Lines
2006
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
1999 Standout
Gastric cancer
2016 Standout
The biology of erbB-2/nue/HER-2 and its role in cancer
1994
Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging
2006 Standout
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Involvement of tyrosine phosphorylation of p185c-erbB2/neu in tumorigenicity induced by x-rays and theneu oncogene in human breast epithelial cells
1998
Targeting cancer metabolism: a therapeutic window opens
2011
Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer
2004 Standout
Chemoradiation for upper aerodigestive tract cancer: balancing evidence from clinical trials with individual patient recommendations
2003
Hypoxia targeted bifunctional suicide gene expression enhances radiotherapy in vitro and in vivo
2012
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis
2007 Standout
Chemoradiotherapy of Locally Advanced Esophageal Cancer
1999 Standout
International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus
2014
Resection for Esophageal Cancer: Strategies for Optimal Management
2008
Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial
2005
Genetics and genomics of radiotherapy toxicity: towards prediction
2011
Imaging in the era of molecular oncology
2008 StandoutNature
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
2006 Standout
Radiomics: Images Are More than Pictures, They Are Data
2015 Standout
Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis
2007
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
2008
Esophageal Cancer
2003 Standout
Cancer stem cells revisited
2017 Standout
Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck
2004 Standout
Prevention of VTE in Nonsurgical Patients
2012 Standout
CALGB 9380: a prospective trial of the feasibility of thoracoscopy/laparoscopy in staging esophageal cancer
2001
Impact of EUS-guided fine-needle aspiration on lymph node staging in patients with esophageal carcinoma
2001
Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study
2008 Standout
Colorectal cancer
2019 Standout
Histologic Tumor Type Is an Independent Prognostic Parameter in Esophageal Cancer: Lessons From More Than 1,000 Consecutive Resections at a Single Center in the Western World
2001
Antithrombotic Therapy for VTE Disease
2012 Standout
Fibroblast growth factor signalling: from development to cancer
2010 Standout
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Chemoradiotherapy Followed by Surgery Compared with Surgery Alone in Squamous-Cell Cancer of the Esophagus
1997
Curative Resection for Esophageal Adenocarcinoma
2001
Chemoradiotherapy for localized esophageal cancer: regimen selection and molecular mechanisms of radiosensitization
2007
Oesophageal carcinoma
2013 Standout
Epigenetic treatment of solid tumours: a review of clinical trials
2015
Prevention of Venous Thromboembolism
2004 Standout
Long-Term Results of a Phase II Trial of Neoadjuvant Chemotherapy Followed by Esophagectomy for Locally Advanced Esophageal Neoplasm
2008
Radionuclide 131I labeled reduced graphene oxide for nuclear imaging guided combined radio- and photothermal therapy of cancer
2015
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
2017 Standout
Update on HER-2 as a target for cancer therapy: The ERBB2 promoter and its exploitation for cancer treatment
2001
NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancer
2000 Standout
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
2008 Standout
Gastric cancer
2020 Standout
Understanding the Intersections between Metabolism and Cancer Biology
2017 Standout
Prevention of Venous Thromboembolism
2008 Standout
Chemotherapy Followed by Surgery Compared with Surgery Alone for Localized Esophageal Cancer
1998
Ivor Lewis esophagogastrectomy for esophageal cancer
2001
Clonal evolution in cancer
2012 StandoutNature
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial
2007
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
2014 Standout
Transhiatal Esophagectomy: Clinical Experience and Refinements
1999
Downregulation of miR-210 expression inhibits proliferation, induces apoptosis and enhances radiosensitivity in hypoxic human hepatoma cells in vitro
2012
Creation of human tumour cells with defined genetic elements
1999 StandoutNature
Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies.
1998
Biopsy-negative malignant esophageal stricture: diagnosis by endoscopic ultrasound
1998
Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers
2003
c-erbB-4 protein expression in human breast cancer
2000
Esophageal cancer: results of an American College of Surgeons patient care evaluation study1
2000
Does Paclitaxel Improve the Chemoradiotherapy of Locoregionally Advanced Esophageal Cancer? A Nonrandomized Comparison With Fluorouracil-Based Therapy
2000
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer
2018 Standout
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
2001 Standout
Whole Body 18FDG-PET and the Response of Esophageal Cancer to Induction Therapy: Results of a Prospective Trial
2003
Engineering Multifunctional RNAi Nanomedicine To Concurrently Target Cancer Hallmarks for Combinatorial Therapy
2017
Predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review
2015
Randomized Trial of Preoperative Chemoradiation Versus Surgery Alone in Patients With Locoregional Esophageal Carcinoma
2001
Type 1 growth factor receptors: an overview of recent developments
1995
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Surgical Management of Esophageal Carcinoma
1999
Engineering Multifunctional RNAi Nanomedicine To Concurrently Target Cancer Hallmarks for Combinatorial Therapy
2017
Adjuvant Chemotherapy for Resected Adenocarcinoma of the Esophagus, Gastro-Esophageal Junction, and Cardia: Phase II Trial (E8296) of the Eastern Cooperative Oncology Group
2004
Phase II Trial of Weekly Irinotecan Plus Cisplatin in Advanced Esophageal Cancer
1999
Recent advances in functional nanomaterials for light–triggered cancer therapy
2018
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
2002 Standout
Management of Gastroesophageal Tumors
2007
Chemodynamic Therapy: Tumour Microenvironment‐Mediated Fenton and Fenton‐like Reactions
2018 Standout
Global cancer statistics, 2012
2015 Standout
Chronic Inflammation and Cytokines in the Tumor Microenvironment
2014 Standout
Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase
1995 StandoutScience
Pleiotropic effects of FGFR1 on cell proliferation, survival, and migration in a 3D mammary epithelial cell model
2005
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781
2008
Phase III Comparison of Preoperative Chemotherapy Compared With Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Esophagogastric Junction
2009
Works of Donal Hollywood being referenced
Primary thromboprophylaxis for cancer patients with central venous catheters – a reappraisal of the evidence
2006
Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy
2011
A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines.
1993
Hypoxia, notch signalling, and prostate cancer
2013
A Comparison of Multimodal Therapy and Surgery for Esophageal Adenocarcinoma
1996 Standout
Hypoxia response element‐driven cytosine deaminase/5‐fluorocytosine gene therapy system: a highly effective approach to overcome the dynamics of tumour hypoxia and enhance the radiosensitivity of prostate cancer cellsin vitro
2008
18FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response
2006
Neoadjuvant chemoradiation may increase the risk of respiratory complications and sepsis after transthoracic esophagectomy
2006
Increased spontaneous apoptosis, but not survivin expression, is associated with histomorphologic response to neoadjuvant chemoradiation in rectal cancer
2009
Achieving hypoxia-inducible gene expression in tumours
2005
Hypoxia in prostate cancer: A powerful shield against tumour destruction?
2008
DNA mismatch repair and the DNA damage response to ionizing radiation: Making sense of apparently conflicting data
2010
Intensity modulated radiation therapy (IMRT) may reduce the oesophageal toxicity of hypofractionated accelerated 3-D radiation for non small cell lung carcinoma
2004